Lipocine price target lowered to $33 from $36 at Ladenburg

Ladenburg analyst Matthew Kaplan lowered the firm’s price target on Lipocine to $33 from $36 and keeps a Buy rating on the shares. The analyst says the company had a successful meeting with FDA in October where an agreement was reached on the exposure parameters and criteria for a single confirmatory pivotal PK study comparing LPCN 1154 to IV brexanolone infusion. The firm is encouraged by the positive feedback from the FDA and looks forward to the study results in Q2 of 2024. It cites the coming termination of the Tlando licensing agreement for the target drop.